COVID-19 continues to pose major problems in the winter in the USA. Infections and hospitalizations are increasing and there is a fear of emergence of new variants. Therapeutic tools are also evolving. We discuss these new developments!
Watch the video version via: https://youtu.be/ElnahBl53e8
Topics discussed: The latest facts on COVID Current therapeutic approaches including antivirals and monoclonal antibodies Future perspectives for the coming year on COVID-19. Guests: Adarsh Bhimraj, MD. Director of Education and Fellowships, Division of Infectious Diseases, Houston Methodsit Hospital. Chair IDSA Guidelines for COVID-19. This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias.
AAC is available at https://asm.org/aac.
Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates.
Subscribe to the podcast at https://asm.org/eic
We can probably all agree that any false positive test result is bad, but I think it’s safe to say that some false positives, like a false positive HIV test for example, is much more anxiety provoking than others. And when it comes to HIV, there have been a number of key advances in the field...
Novel β-lactamase/β-lactamase inhibitors have become critical drugs to combat the most resistant Gram-negative infections. A series of new compounds with even more broad and potent activity are in the horizon to add to the therapeutic armamentarium. Today, we will discuss these drugs with experts...